Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Queensland Health
Deloitte
Teva
Julphar
US Army
UBS
Boehringer Ingelheim

Generated: August 17, 2018

DrugPatentWatch Database Preview

ALTACE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Altace patents expire, and when can generic versions of Altace launch?

Altace is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the ramipril profile page.

Drug patent expirations by year for ALTACE
Pharmacology for ALTACE
Medical Subject Heading (MeSH) Categories for ALTACE
Synonyms for ALTACE
(2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester
(2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester
(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p
(2S,3AS,6AS)-1-((S)-2-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)PROPANOYL)-OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLIC ACID
(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure
(2S,3AS,6AS)-1-[(2S)-2-([(2S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YL]AMINO)PROPANOYL]-OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLIC ACID
(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name)
(2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
(2S,3AS,6AS)-1-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-OCTAHYDRO-CYCLOPENTA[B]PYRROLE-2-CARBOXYLIC ACID
(2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic
(2S,3AS,6AS)-1((S)-N-((S)-1-CARBOXY-3-PHENYLPROPYL)ALANYL)OCTAHYDROCYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID 1-ETHYL ESTER
[2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen
[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]pyrrole-2-carboxylic acid(Ramipril)
126613-39-6
333R195
4-[2-(1-ethoxycarbonyl-3-phenyl-propyl)aminopropanoyl]-4-azabicyclo[3.3.0]octane-3-carboxylic acid
87333-19-5
88094-EP2270011A1
88094-EP2272841A1
88094-EP2277879A1
88094-EP2287165A2
88094-EP2287166A2
88094-EP2292620A2
88094-EP2298742A1
88094-EP2298776A1
88094-EP2298779A1
88094-EP2301923A1
88094-EP2301931A1
88094-EP2301936A1
88094-EP2305648A1
AB0008490
AB00698339_09
AB00698339_10
AB00698339-07
AB00698339-08
AB07503
AB2000297
AC-1347
AC1NSFPR
Acovil
AK163187
AKOS005622534
Almirall Brand of Ramipril
Altace (TN)
AM015032
AN-15038
Astra Brand of Ramipril
AstraZeneca Brand of Ramipril
Aventis Brand of Ramipril
Aventis Pharma Brand of Ramipril
B2208
BBL033964
BC205360
BDBM50084681
BIDD:GT0803
Bio-0651
BSPBio_003347
C23H32N2O5
Carasel
Cardace
CAS-87333-19-5
CCG-100833
CHEBI:8774
CHEMBL1168
CPD000466386
CS-2270
CTK8G2889
Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-
Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S(1(R*(R*)),2alpha,3abeta,6abeta))-
D00421
D01STB
DB00178
Delix
DR002533
DSSTox_CID_3551
DSSTox_GSID_23551
DSSTox_RID_77077
DTXSID8023551
GTPL6339
HDACQVRGBOVJII-JBDAPHQKSA-N
HMS2051E04
HMS2090L11
HMS2093M10
HMS2231M05
HMS3259J07
HOE 498
Hoe-498
HOE498
Hoechst Brand of Ramipril
HY-B0279
Hypren
Hytren
J90014
KBio2_002504
KBio2_005072
KBio2_007640
KBio3_002849
KBioGR_001858
KBioSS_002512
KS-1103
L35JN3I7SJ
Lostapres
LS-58199
MCULE-5386328912
MFCD00865775
MLS000759523
MLS001216547
MLS001423965
MolPort-001-736-571
Monarch Brand of Ramipril
N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid
Naprix
NC00083
NC00627
NCGC00016955-01
NCGC00178127-01
NCGC00178127-02
NE42859
NPD2431
NSC-758933
NSC758933
Pharmakon1600-01505214
Pramace
Pramace (discontinued)
Prilace
Promed Brand of Ramipril
Quark
Ramace
ramipril
Ramipril (Altace)
Ramipril (USP/INN)
Ramipril [USAN:INN:BAN]
Ramipril [USAN:USP:INN:BAN]
Ramipril, >=98% (HPLC)
Ramipril, British Pharmacopoeia (BP) Reference Standard
Ramipril, European Pharmacopoeia (EP) Reference Standard
Ramipril, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Ramipril, United States Pharmacopeia (USP) Reference Standard
Ramiprilum
Ramiprilum [Latin]
Ramipro
Ramipro, Tritace, Altace, Prilace, Ramipril
Ramipro;Tritace;Prilace;Altace
s1793
SAM001246757
SAM002699899
SBI-0206728.P001
SC-17348
SCHEMBL16059
SMR000466386
Spectrum_001958
SPECTRUM1505214
Spectrum3_001794
Spectrum4_001269
Spectrum5_001721
SR-05000001908
SR-05000001908-2
STK801937
Tox21_110708
Tox21_110708_1
Triatec
Tritace
Tritace (TN)
UNII-L35JN3I7SJ
Unipril
Vesdil
Z1946144927
Zabien
ZINC3798757

US Patents and Regulatory Information for ALTACE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ALTACE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-001 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ALTACE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/047 United Kingdom ➤ Try a Free Trial PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
80030 Netherlands ➤ Try a Free Trial PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
C0001 Belgium ➤ Try a Free Trial PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Mallinckrodt
AstraZeneca
Queensland Health
Fuji
Colorcon
Farmers Insurance
UBS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.